Precipio Inc (PRPO) - Total Liabilities
Based on the latest financial reports, Precipio Inc (PRPO) has total liabilities worth $7.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Precipio Inc (PRPO) cash flow conversion to assess how effectively this company generates cash.
Precipio Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Precipio Inc's total liabilities have evolved over time, based on quarterly financial data. Check PRPO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Precipio Inc Competitors by Total Liabilities
The table below lists competitors of Precipio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advance NanoTek Limited
F:BBJ
|
Germany | €3.36 Million |
|
Dayou A-Tech
KO:002880
|
Korea | ₩312.23 Billion |
|
Rotork PLC
LSE:ROR
|
UK | GBX177.10 Million |
|
nTels Co. Ltd
KQ:069410
|
Korea | ₩12.49 Billion |
|
Chin Yang Chem
KO:051630
|
Korea | ₩41.35 Billion |
|
Bitcoin Depot Inc.
NASDAQ:BTM
|
USA | $118.61 Million |
|
Kuk Young G&M Co. Ltd
KQ:006050
|
Korea | ₩24.28 Billion |
|
Brand Concepts Limited
NSE:BCONCEPTS
|
India | Rs2.50 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Precipio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Precipio Inc (PRPO) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precipio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precipio Inc (1999–2024)
The table below shows the annual total liabilities of Precipio Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.90 Million | +33.50% |
| 2023-12-31 | $3.67 Million | -28.52% |
| 2022-12-31 | $5.14 Million | -11.96% |
| 2021-12-31 | $5.83 Million | -10.93% |
| 2020-12-31 | $6.55 Million | +3.89% |
| 2019-12-31 | $6.31 Million | -59.27% |
| 2018-12-31 | $15.48 Million | +8.76% |
| 2017-12-31 | $14.23 Million | -30.93% |
| 2016-12-31 | $20.61 Million | +16.86% |
| 2015-12-31 | $17.64 Million | -24.80% |
| 2014-12-31 | $23.45 Million | +24.54% |
| 2013-12-31 | $18.83 Million | +1.70% |
| 2012-12-31 | $18.52 Million | -17.75% |
| 2011-12-31 | $22.51 Million | -4.31% |
| 2010-12-31 | $23.53 Million | +441.85% |
| 2009-12-31 | $4.34 Million | -0.21% |
| 2008-12-31 | $4.35 Million | -12.77% |
| 2007-12-31 | $4.99 Million | -6.40% |
| 2006-12-31 | $5.33 Million | -28.32% |
| 2005-12-31 | $7.43 Million | -64.47% |
| 2004-12-31 | $20.92 Million | +70.83% |
| 2003-12-31 | $12.25 Million | -2.18% |
| 2002-12-31 | $12.52 Million | +74.34% |
| 2001-12-31 | $7.18 Million | +84.30% |
| 2000-12-31 | $3.90 Million | -82.34% |
| 1999-12-31 | $22.06 Million | -- |
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomar… Read more